Evotec Accelerates Access to Biologic Therapeutics with Initiation of Manufacturing Facility in Toulouse
April 20, 2021 at 01:30 am EDT
Share
Evotec SE announced that it has initiated the construction of its J.POD(R) 2 EU biologics manufacturing facility at the company’s Campus Curie in Toulouse, France. J.POD(R) 2 EU, Evotec's second innovative cGMP biomanufacturing facility, will employ Just - Evotec Biologics' cutting-edge technology that utilizes small, automated, highly intensified and continuous bioprocessing operations housed inside autonomous cleanrooms. J.POD(R) 2 EU will be the company’s first commercial biomanufacturing facility in Europe and is anticipated to deliver much needed capacity, flexibility and quality for biotherapeutic development and manufacturing. The construction of the company’s first J.POD(R) 1 US in Redmond, Washington is proceeding on schedule and will be fully operational in second half of 2021. With its wholly owned subsidiary, Just - Evotec Biologics, Evotec is ideally positioned to build the capacity required for the fight against COVID-19 and future pandemic threats delivering rapid, high quality outcomes. The company is supporting multiple projects against COVID-19, including partnerships with the Bill & Melinda Gates Foundation and the United States Department of Defense. In addition to J.POD(R) technology, the company is building unparalleled data-driven scientific capabilities to meet future viral threats, which include fast discovery, optimisation and development of novel therapeutic agents. The build-up of J.POD(R) 2 EU will be supported with up to €50 million from the French government, the Occitanie Region, Bpifrance, the Haute-Garonne prefecture as well as Toulouse Métropole. The total investment hat Evotec plans to undertake is currently estimated at approx. €150 million. The company’s Toulouse site, the Campus Curie, was recently expanded through the acquisition of "Biopark by Sanofi." Evotec has been operating in France since 2015. Construction of the J.POD(R) 2 EU facility is expected to begin in second half of 2021 and is expected to be fully operational in 2023.
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women's health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.